Bioimplants Market – By Type (Cardiovascular, Orthopedic, Ophthalmic), Material Type (Biomaterial Metal, Alloys, Ceramic), Application (Cardiac Surgery, Trauma and Orthopedic Surgery, Ophthalmic), End-use (Hospitals, ASCs), Global Forecast (2024 – 2032)

Bioimplants Market Size

Bioimplants Market size in 2023 was valued at USD 132 billion and is anticipated to experience growth at a CAGR of 8.2% from 2024 to 2032. High market growth can be attributed to the increasing prevalence of chronic diseases and conditions, such as cardiovascular diseases, orthopedic disorders, and ophthalmic diseases, which require bioimplants for treatment and management.
 

Additionally, the rising geriatric population, which is more susceptible to these chronic conditions, is further driving the demand for bioimplants. Further, technological advancements in the field, such as the development of biocompatible materials and 3D printing techniques, are also fueling market growth by improving the effectiveness and lifespan of bioimplants. Moreover, the growing preference for minimally invasive surgeries, which require bioimplants for procedures like joint replacements and dental implants, is contributing to market expansion.
 

Bioimplants are medical devices that are implanted into the body to replace a missing biological structure, support a damaged biological structure, or enhance an existing biological structure. These implants can be made from a variety of materials, including metals, ceramics, and polymers, and they are designed to integrate with the body's tissues or perform specific functions within the body.
 

Bioimplants Market Trends

• The increasing elderly population globally, coupled with the rising prevalence of chronic diseases, is a significant driver of growth in the market. As people age, they are more prone to conditions such as osteoarthritis, cardiovascular diseases, and dental issues which often require the use of bioimplants for treatment.
   
• For instance, as per the National Institute of Health (NIH), the prevalence of chronic diseases in the geriatric population in the U.S. is high, with almost 90% of the population having at least one chronic disease. The most common chronic diseases in the geriatric population include hypertension, arthritis, diabetes, heart disease, and cancer.
   
• Bioimplants offer a range of benefits, including improved mobility, reduced pain, and enhanced quality of life for these patients.
   
• Further, with advancements in technology and materials, bioimplants have become increasingly effective and reliable, further fueling their demand.
   

Bioimplants Market Analysis

Based on type, the market is segmented into cardiovascular implants, orthopedic implants, ophthalmic implants, spinal implants, dental implants, and breast implants. The orthopedic implants segment is further segmented into joint implants, bone implants, and soft tissue implants. The cardiovascular implants segment accounted for USD 47.4 billion in 2023.
 

• The increasing prevalence of cardiovascular diseases globally has led to a growing demand for advanced treatment options, including implantable medical devices.
   
• Additionally, technological advancements in cardiovascular implants, such as stents, pacemakers, and implantable defibrillators, have improved their efficacy and safety, driving adoption rates.
   
• Furthermore, favorable reimbursement policies and increasing healthcare expenditure in developed and developing countries have also played a significant role in the market's growth, making cardiovascular implants a crucial segment within the market.
   

Based on material type, the bioimplants market is segmented into biomaterial metal, alloys, ceramic, and polymers. The biomaterial metal segment is further categorized into titanium, gold, silver, and platinum. The biomaterial metal segment dominated the market with 42.3% of market share in 2023.
 

• The biomaterial metal segment holds a significant share in the market, driven by its unique properties and wide applications. Metals like titanium, stainless steel, and cobalt-chromium alloys are favored for their biocompatibility, strength, and corrosion resistance, making them ideal for various implantable devices.
   
• Additionally, the ability of biomaterial metals to be fabricated into complex shapes and structures also enhances their suitability for various implant types and patient needs.
   
• Furthermore, ongoing advancements in metallurgy and surface treatments have improved the biocompatibility and osseointegration of these materials, further boosting their adoption.
   

Based on application, the bioimplants market is categorized into cardiac surgery, trauma and orthopedic surgery, ophthalmic surgery, neurological surgery, dental surgery, and cosmetic and reconstructive surgery. The cardiac surgery segment dominated the market and predicted to grow at CAGR of 7.9% over the forecast period.
 

• The increasing prevalence of cardiovascular diseases worldwide has led to a rising number of cardiac surgeries, thereby boosting the segmental growth. Bioimplants, including heart valves, stents, and pacemakers, play a crucial role in these procedures, driving demand within the cardiac surgery segment.
   
• For instance, as per the American Heart Association (AHA), More than 600 000 coronary stents are implanted during percutaneous coronary interventions (PCIs) annually in the U.S.
   
• Additionally, advancements in bioimplant technologies, such as the development of bioresorbable stents and tissue-engineered heart valves, have further boosted segmentl growth.
   

Based on end-use, the bioimplants market is segmented into hospitals, specialty clinics, Ambulatory Surgical Centers (ASCs), and other end-users. The hospitals segment held highest market share in 2023 and is anticipated to reach USD 118.2 billion by 2032.
 

• Hospitals are the primary centers for surgical procedures, where bioimplants such as orthopedic implants, cardiac implants, and dental implants are commonly used.
   
• Additionally, hospitals often have the necessary infrastructure and skilled medical professionals to perform complex implant procedures, making them the preferred choice for patients requiring such treatments.
   
• Moreover, hospitals frequently have access to advanced medical technologies and can offer comprehensive post-operative care, ensuring the success and longevity of bioimplants, which further solidifies their position as major end-users in the market.
   

North America bioimplants market was valued at USD 48.6 billion in 2023 and is anticipated to grow at a CAGR of 7.9% over the forecast years.
 

• The region benefits from a robust healthcare infrastructure, advanced technological innovations, and high healthcare expenditure.
   
• Additionally, favorable reimbursement policies and increasing awareness about the benefits of bioimplants contribute to the market's growth.
   
• Further, presence of major market players and research institutions focused on developing novel bioimplants propels the regional market growth.
   

U.S. bioimplants market is anticipated to grow at CAGR of 7.8% during the analysis timeframe.
 

• The country benefits from a strong network of healthcare providers and facilities that are well-equipped to handle complex implant procedures, leading to a higher adoption rate of bioimplants.
   
• Moreover, the U.S. has a favorable reimbursement landscape for medical procedures involving bioimplants, making these treatments more accessible to a larger population.
   
• Additionally, high healthcare expenditure in the country and a significant patient population, further enhances the market growth.
   

UK is anticipated to witness robust growth in the global bioimplants market.
 

• A growing elderly population with increasing healthcare needs is driving the demand for bioimplants in the country.
   
• Additionally, the presence of leading medical device manufacturers and research institutions in the UK contributes to the development and commercialization of innovative bioimplant technologies, further fueling market expansion.
   

China bioimplants market is anticipated to witness lucrative growth between 2024 – 2032.
 

• One major factor is the country's large and aging population, which creates a significant demand for orthopedic and dental implants to address age-related issues such as osteoarthritis and tooth loss.
   
• Furthermore, the growing healthcare infrastructure and rising disposable income in the country are enabling more people to afford advanced medical treatments, including bioimplant surgeries, thereby boosting market growth.
   

South Korea bioimplants market is expected to grow significantly over the years.
 

• Factors such as a rapidly aging population, increasing prevalence of chronic diseases, and advancements in healthcare infrastructure are driving the demand for bioimplants in the country.
   
• Additionally, South Korea's strong focus on research and development in the medical field, coupled with government initiatives to promote medical tourism, further contribute to the growth of the market.
   

Bioimplants Market Share

The bioimplants industry is characterized by intense competition among key players striving to improve patient outcomes and address unmet medical needs. Inorganic growth initiatives such as partnerships, mergers, and acquisitions are common strategies employed by players to expand their market presence, enhance their product portfolios, and gain a competitive advantage.
 

Bioimplants Market Companies

Prominent players operating in the bioimplants industry include:

• Abbott Laboratories
• Arthrex inc.
• aap Implantate AG
• Biotronik SE & Co. KG
• Cochlear Ltd.
• DePuy Synthes (Johnson & Johnson)
• Edwards Lifesciences Corporation
• LifeNet Health
• Medtronic plc
• Organogenesis Inc.
• Smith & Nephew plc
• Stryker Corporation
• Zimmer Biomet Holdings Inc.
   

Bioimplants Industry News

• In January 2023, Arthrex received FDA clearance for its TightRope implant for pediatric indications. This implant is used in the surgical treatment of orthopedic injuries and is the first and only fixation device for anterior cruciate ligament (ACL) injuries cleared for pediatric use. This helped the company expand its product offerings and cater to a larger customer base.
   
• In November 2020, Medtronic completed the acquisition of Medicrea, a French spinal implant maker known for its artificial intelligence (AI), predictive modeling, and patient-specific implants. The acquisition expands Medtronic's artificial intelligence and data capabilities, making it the first company to offer an integrated spine solution that includes AI-driven surgical planning, personalized spinal implants, and robotic-assisted surgery.
   

The bioimplants market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Cardiovascular implants
• Orthopedic implants
  • Joint implants
  • Bone implants
  • Soft tissue implants
• Ophthalmic implants
• Spinal implants
• Dental implants
• Breast implants

Market, By Material Type

• Biomaterial metal
  • Titanium
  • Gold
  • Silver
  • Platinum
• Alloys
• Ceramic
• Polymers

Market, By Application

• Cardiac surgery
• Trauma and orthopedic surgery
• Ophthalmic surgery
• Neurological surgery
• Dental surgery
• Cosmetic and reconstructive surgery

Market, By End-use

• Hospitals
• Specialty clinics
• ASCs
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa